Splash Beverage finalizes joint venture with cannabinoid pharma group for CannEpil veterinary program
SBEV•Joint venture to lead veterinary development
- Splash Beverage Group is finalizing a joint venture with an established cannabinoid pharmaceutical company to lead CannEpil’s veterinary drug development program.
- The move follows an expansion of Splash’s exclusive global CannEpil license into veterinary therapeutics, adding a second FDA-regulated development platform.
- Initial veterinary focus targets companion-animal oncology and chronic pain management, with canine indications first.
- Splash expects the partner to bring executives with experience advancing cannabinoid medicines through regulatory approval, with more details to be announced soon.
- Splash will pay Argent BioPharma a 10% royalty on net revenues from veterinary CannEpil applications.
